Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.83 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.72 |
| ▸ | PDE5A | O76074 | 3/20 | 0.71 |
| ▸ | GBA1 | P04062 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063103 | 0.85 | ABCG2 (1.00) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL27066418 | 0.84 | ABCG2 (0.72) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL22201628 | 0.84 | ABCG2 (0.83) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1061916 | 0.84 | ABCG2 (1.00) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13945461 | 0.84 | MEN1 (0.97) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5104228 | 0.83 | ABCG2 (1.00) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16404312 | 0.83 | ABCG2 (0.72) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1083771 | 0.82 | MEN1 (0.98) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14262896 | 0.81 | ABCG2 (0.68) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5104461 | 0.81 | ABCG2 (0.79) | ABCG2MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | ABCG2 713/4885MEN1 3779/4885KMT2A 4519/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | ABCG2 439/4885MEN1 3843/4885KMT2A 4668/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | ABCG2 713/4885MEN1 3779/4885KMT2A 4519/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | ABCG2 336/4885MEN1 3792/4885KMT2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.